114 related articles for article (PubMed ID: 3864428)
21. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
Dayer P; Kronbach T; Eichelbaum M; Meyer UA
Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
[TBL] [Abstract][Full Text] [Related]
22. Is the metabolism of alfentanil subject to debrisoquine polymorphism? A study using human liver microsomes.
Lavrijsen KL; Van Houdt JM; Van Dyck DM; Hendrickx JJ; Woestenborghs RJ; Lauwers W; Meuldermans WE; Heykants JJ
Anesthesiology; 1988 Oct; 69(4):535-40. PubMed ID: 3140691
[TBL] [Abstract][Full Text] [Related]
23. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.
Yue QY; Svensson JO; Alm C; Sjöqvist F; Säwe J
Br J Clin Pharmacol; 1989 Dec; 28(6):639-45. PubMed ID: 2611086
[TBL] [Abstract][Full Text] [Related]
24. Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation.
Gut J; Gasser R; Dayer P; Kronbach T; Catin T; Meyer UA
FEBS Lett; 1984 Aug; 173(2):287-90. PubMed ID: 6146537
[TBL] [Abstract][Full Text] [Related]
25. Tolbutamide hydroxylation by human, rabbit and rat liver microsomes and by purified forms of cytochrome P-450.
Veronese ME; McManus ME; Laupattarakasem P; Miners JO; Birkett DJ
Drug Metab Dispos; 1990; 18(3):356-61. PubMed ID: 1974199
[TBL] [Abstract][Full Text] [Related]
26. Genetically determined oxidation capacity and the disposition of debrisoquine.
Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
[TBL] [Abstract][Full Text] [Related]
27. Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism.
Dahlqvist R; Bertilsson L; Birkett DJ; Eichelbaum M; Säwe J; Sjöqvist F
Clin Pharmacol Ther; 1984 Jun; 35(6):815-21. PubMed ID: 6734034
[TBL] [Abstract][Full Text] [Related]
28. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily.
Veronese ME; Doecke CJ; Mackenzie PI; McManus ME; Miners JO; Rees DL; Gasser R; Meyer UA; Birkett DJ
Biochem J; 1993 Jan; 289 ( Pt 2)(Pt 2):533-8. PubMed ID: 8424795
[TBL] [Abstract][Full Text] [Related]
29. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans.
Rasmussen BB; Brøsen K
Br J Clin Pharmacol; 1997 Mar; 43(3):253-8. PubMed ID: 9088579
[TBL] [Abstract][Full Text] [Related]
30. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.
Llerena A; Alm C; Dahl ML; Ekqvist B; Bertilsson L
Ther Drug Monit; 1992 Apr; 14(2):92-7. PubMed ID: 1585408
[TBL] [Abstract][Full Text] [Related]
31. Determination of a 'GW cocktail' of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry.
Scott RJ; Palmer J; Lewis IA; Pleasance S
Rapid Commun Mass Spectrom; 1999; 13(23):2305-19. PubMed ID: 10567928
[TBL] [Abstract][Full Text] [Related]
32. Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype.
Llerena A; Cobaleda J; Martínez C; Benítez J
Eur J Drug Metab Pharmacokinet; 1996; 21(2):129-38. PubMed ID: 8839686
[TBL] [Abstract][Full Text] [Related]
33. Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.
Distlerath LM; Guengerich FP
Proc Natl Acad Sci U S A; 1984 Dec; 81(23):7348-52. PubMed ID: 6594694
[TBL] [Abstract][Full Text] [Related]
34. Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains.
Küpfer A; Al-Dabbagh SG; Ritchie JC; Idle JR; Smith RL
Biochem Pharmacol; 1982 Oct; 31(20):3193-9. PubMed ID: 7150348
[TBL] [Abstract][Full Text] [Related]
35. Antipyrine metabolism in female Lewis and Dark Agouti strains of rats, which are extensive and poor metabolizers of debrisoquine, respectively.
Tanaka E; Kobayashi S; Uchida E; Oguchi K; Yasuhara H
Jpn J Pharmacol; 1989 Mar; 49(3):433-5. PubMed ID: 2747044
[TBL] [Abstract][Full Text] [Related]
36. Debrisoquine hydroxylation polymorphism and personality.
Bertilsson L; Alm C; De Las Carreras C; Widen J; Edman G; Schalling D
Lancet; 1989 Mar; 1(8637):555. PubMed ID: 2564084
[No Abstract] [Full Text] [Related]
37. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
Danhof M; Idle JR; Teunissen MW; Sloan TP; Breimer DD; Smith RL
Pharmacology; 1981; 22(6):349-58. PubMed ID: 7267701
[TBL] [Abstract][Full Text] [Related]
38. Cytochrome P450 isozymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes.
Suzuki T; Fujita S; Narimatsu S; Masubuchi Y; Tachibana M; Ohta S; Hirobe M
FASEB J; 1992 Jan; 6(2):771-6. PubMed ID: 1537468
[TBL] [Abstract][Full Text] [Related]
39. Tolbutamide 4-hydroxylase activity of human liver microsomes: effect of inhibitors.
Purba HS; Back DJ; Orme ML
Br J Clin Pharmacol; 1987 Aug; 24(2):230-4. PubMed ID: 3620298
[TBL] [Abstract][Full Text] [Related]
40. Genetic predisposition to Balkan endemic nephropathy: ability to hydroxylate debrisoquine as a host risk factor.
Nikolov IG; Chernozemsky IN; Idle JR
IARC Sci Publ; 1991; (115):289-96. PubMed ID: 1820343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
